Document:

<PAGE>

                       MORGAN STANLEY SELECT EQUITY TRUST
                      SELECT 5 INDUSTRIAL PORTFOLIO 2001-2
                            REFERENCE TRUST AGREEMENT

          This Reference Trust Agreement dated April 2, 2001 between MORGAN
STANLEY DW INC., as Depositor, and The Chase Manhattan Bank, as Trustee, sets
forth certain provisions in full and incorporates other provisions by reference
to the document entitled "Sears Equity Investment Trust, Trust Indenture and
Agreement" dated January 22, 1991, as amended on March 16, 1993, July 18, 1995
and December 30, 1997 (the "Basic Agreement"). Such provisions as are
incorporated by reference constitute a single instrument (the "Indenture").

                                WITNESSETH THAT:

          In consideration of the premises and of the mutual agreements herein
contained, the Depositor and the Trustee agree as follows:

                                       I.

                     STANDARD TERMS AND CONDITIONS OF TRUST

          Subject to the provisions of Part II hereof, all the provisions
contained in the Basic Agreement are herein incorporated by reference in their
entirety and shall be deemed to be a part of this instrument as fully and to the
same extent as though said provisions had been set forth in full in this
instrument except that the Basic Agreement is hereby amended in the following
manner:

          A.   Article I, Section 1.01, paragraph (29) defining "Trustee" shall
               be amended as follows:

          "'Trustee' shall mean The Chase Manhattan Bank, or any successor
          trustee appointed as hereinafter provided."

          B.   Reference to United States Trust Company of New York in its
               capacity as Trustee is replaced by The Chase Manhattan Bank
               throughout the Basic Agreement.

          C.   Reference to "Dean Witter Select Equity Trust" is replaced by
               "Morgan Stanley Select Equity Trust".

          D.   Section 3.01 is amended to substitute the following:

               SECTION 3.01. INITIAL COST The costs of organizing the Trust and
          sale of the Trust
<PAGE>

          Units shall, to the extent of the expenses reimbursable to the
          Depositor provided below, be borne by the Unit Holders, PROVIDED,
          HOWEVER, that, to the extent all of such costs are not borne by Unit
          Holders, the amount of such costs not borne by Unit Holders shall be
          borne by the Depositor and, PROVIDED FURTHER, HOWEVER, that the
          liability on the part of the Depositor under this section shall not
          include any fees or other expenses incurred in connection with the
          administration of the Trust subsequent to the deposit referred to in
          Section 2.01. Upon notification from the Depositor that the primary
          offering period is concluded, the Trustee shall withdraw from the
          Account or Accounts specified in the Prospectus or, if no Account is
          therein specified, from the Principal Account, and pay to the
          Depositor the Depositor's reimbursable expenses of organizing the
          Trust and sale of the Trust Units in an amount certified to the
          Trustee by the Depositor. If the balance of the Principal Account is
          insufficient to make such withdrawal, the Trustee shall, as directed
          by the Depositor, sell Securities identified by the Depositor, or
          distribute to the Depositor Securities having a value, as determined
          under Section 4.01 as of the date of distribution, sufficient for such
          reimbursement. The reimbursement provided for in this section shall be
          for the account of the Unitholders of record at the conclusion of the
          primary offering period and shall not be reflected in the computation
          of the Unit Value prior thereto. As used herein, the Depositor's
          reimbursable expenses of organizing the Trust and sale of the Trust
          Units shall include the cost of the initial preparation and
          typesetting of the registration statement, prospectuses (including
          preliminary prospectuses), the indenture, and other documents relating
          to the Trust, SEC and state blue sky registration fees, the cost of
          the initial valuation of the portfolio and audit of the Trust, the
          initial fees and expenses of the Trustee, and legal and other
          out-of-pocket expenses related thereto, but not including the expenses
          incurred in the printing of preliminary prospectuses and prospectuses,
          expenses incurred in the preparation and printing of brochures and
          other advertising materials and any other selling expenses.
<PAGE>

          Any cash which the Depositor has identified as to be used for
          reimbursement of expenses pursuant to this Section shall be reserved
          by the Trustee for such purpose and shall not be subject to
          distribution or, unless the Depositor otherwise directs, used for
          payment of redemptions in excess of the per-Unit amount allocable to
          Units tendered for redemption.

          E.   Reference to "Dean Witter Reynolds Inc." is replaced by "Morgan
               Stanley DW Inc."

                                       II.

                      SPECIAL TERMS AND CONDITIONS OF TRUST

          The following special terms and conditions are hereby agreed to:

          A. The Trust is denominated Morgan Stanley Select Equity Trust
     Select 5 Industrial Portfolio 2001-2 (the "Select 5 Trust").

          B. The publicly traded stocks listed in Schedule A hereto are those
     which, subject to the terms of this Indenture, have been or are to be
     deposited in trust under this Indenture.

          C. The term, "Depositor" shall mean Morgan Stanley DW Inc.

          D. The aggregate number of Units referred to in Sections 2.03 and 9.01
     of the Basic Agreement is 25,052 for the Select 5 Trust.

          E. A Unit is hereby declared initially equal to 1/25,052nd for the
     Select 5 Trust.

          F. The term "In-Kind Distribution Date" shall mean June 11, 2002.

          G. The term "Record Dates" shall mean November 1, 2001, February 1,
     2002, and July 1, 2002 and such other date as the Depositor may direct.

          H. The term "Distribution Dates" shall mean November 15, 2001,
     February 15, 2002 and on or about July 8, 2002 and such other date as the
     Depositor may direct.

          I. The term "Termination Date" shall mean July 1, 2002.
<PAGE>

          J. The Depositor's Annual Portfolio Supervision Fee shall be a maximum
     of $0.25 per 100 Units.

          K. The Trustee's annual fee as defined in Section 6.04 of the
     Indenture shall be $0.90 per 100 Units if the greatest number of Units
     outstanding during the period is 10,000,000 or more; $0.96 per 100 Units if
     the greatest number of Units outstanding during the period is between
     5,000,000 and 9,999,999; and $1.00 per 100 Units if the greatest number of
     Units outstanding during the period is 4,999,999 or less.

          L. For a Unit Holder to receive an "in-kind" distribution during the
     life of the Trust, such Unit Holder must tender at least 25,000 Units for
     redemption. There is no minimum amount of Units that a Unit Holder must
     tender in order to receive an "in-kind" distribution on the In-Kind Date or
     in connection with a rollover.

          M. Paragraph (b)(ii) of Section 9.03 is amended to provide that the
     period during which the Trustee shall liquidate the Trust Securities shall
     not exceed 14 business days commencing on the first business day following
     the In- Kind Date.
<PAGE>

          (Signatures and acknowledgments on separate pages)
<PAGE>

          The Schedule of Portfolio Securities in the prospectus included in
this Registration Statement is hereby incorporated by reference herein as
Schedule A hereto.<PAGE>

                                                                  Exhibit 10.9

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

                           EXCLUSIVE LICENSE AGREEMENT

         THIS AGREEMENT, including the attached Exhibits, (the "Agreement") is
made and entered into effective as of the 1st day of January, 2000 (the
"Effective Date"), by and among MARVIN J. SLEPIAN, M.D. ("Dr. Slepian"),
ENDOLUMINAL THERAPEUTICS, INC., a Delaware corporation, ("ETI") and FOCAL, INC.,
a Delaware corporation ("Focal").

                                    RECITALS

         A. Dr. Slepian has developed technology related to that certain Field
defined below, certain of which technology is the subject of United States,
European and other patent applications.

         B. Dr. Slepian is the sole shareholder and director, and an officer, of
ETI and has assigned to ETI all rights in and to such technology, including the
patents and patent applications.

         C. Focal desires to acquire, and ETI is willing to grant to Focal, an
exclusive license under such patents and patent applications and know-how to use
such technology, all under the terms set forth below.

         NOW, THEREFORE, for and in consideration of the mutual covenants and
agreements contained herein, the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

         For the purposes of this Agreement, the following defined terms will
have the respective meanings set forth in this Article 1:

         1.1 AFFILIATE. The term "Affiliate" means any person or entity which,
directly or indirectly, owns or controls Focal, or which is controlled by or
under common control with Focal. For purposes of this definition, "control"
means the ownership, directly or indirectly, of twenty percent (20%) or more of
the outstanding equity securities of a corporation entitled to vote in the
election of directors or a fifty percent (50%) or greater interest in the net
assets or profits of an entity which is not a corporation.

         1.2 CONFIDENTIAL INFORMATION. The term "Confidential Information" has
the meaning ascribed in Section 3.4 of this Agreement.

         1.3 CONSULTING AGREEMENT. The term "Consulting Agreement" means that
certain Agreement for Consulting Services dated January 1, 2000 between Focal
and Dr. Slepian, in the form of Exhibit C attached hereto.

         1.4 FIELD. The term "Field" shall mean all human and medical products,
methods and applications of: all materials with or without drugs used for
ectoluminal treatments as defined by the issued claims of the Patent Rights
listed in Exhibit A, and all Focal proprietary materials with or

<PAGE>

without drugs used for endoluminal treatments as defined by the issued claims of
the Patent Rights listed in Exhibit A.

         1.5 IMPROVEMENTS. The term "Improvements" shall mean any and all
inventions, modifications or discoveries related to, but not the subject of,
the Patent Rights only in the Field conceived or developed by Dr. Slepian,
alone or jointly with others, during the term of this Agreement.

However, the Improvements shall not include any Improvements, to the extent that
they are owned by the University of Arizona, or any subsequent primary employer
(but not including consulting and other similar engagements) of Dr. Slepian by
reason of Dr. Slepian's employment by such entity, or to the extent such patents
or applications are owned by Focal under the Consulting Agreement or otherwise.

         1.6 NET REVENUES The term "Net Revenues" mean the gross receipts paid
to Focal or its Affiliates or to Focal from its sublicensees; for sales of
Patented Product(s) worldwide less (a) all trade, quantity and cash discounts
actually allowed and refunded, (b) all credits and allowances actually refunded
on account of rejections, returns, billing errors or retroactive price
reductions, (c) duties and tariffs paid by Focal or its Affiliates, (d) freight
insurance and transportation costs incurred by Focal or its Affiliates, and (e)
excise, sale and use taxes and equivalent taxes paid by Focal or its Affiliates.

         1.7 PATENTED PRODUCT(S). The term "Patented Product(s)"means any
product whose sale or principal intended use would infringe, contributorily
infringe or induce the infringement of one or more Valid Claims of the Patent
Rights in the country in which such product is sold.

         1.8 PATENT RIGHTS. The term "Patent Rights" means the technology which
is the subject of issued patents and patent applications listed in Exhibits A
and B owned by Dr. Slepian and/or ETI and all Improvements thereof.

However, the Patent Rights shall not include any patents or applications, to the
extent that they are owned by the University of Arizona, or any subsequent
primary employer (but not including consulting and other similar engagements) of
Dr. Slepian by reason of Dr. Slepian's employment by such entity, or to the
extent such patents or applications are owned by Focal.

         1.9 VALID CLAIM. The term "Valid Claim" shall mean a claim of an issued
and unexpired patent included within the Patent Rights, which has not been held
unenforceable, unpatentable or invalid by a court or other governmental agency
of competent jurisdiction. In the event that such a holding of unenforceability,
unpatentability or invalidity is reversed on appeal by a higher court or agency
of competent jurisdiction, the subject claim shall be reinstated as a Valid
Claim hereunder.

<PAGE>

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

                                    ARTICLE 2
                               LICENSE AND ROYALTY

         2.1      EXCLUSIVE LICENSE.

                  (a) ETI and Dr. Slepian hereby grant to Focal (i) the
         exclusive worldwide license with the right to sublicense under the
         Patent Rights listed in Exhibit A to develop, manufacture, use, sell,
         exploit and otherwise commercialize any Patented Products, to practice
         any method, process or procedure, and to otherwise exploit the Patent
         Rights listed in Exhibit A, within the Field for the life of the Patent
         Rights, and (ii) the exclusive worldwide license with the right to
         sublicense under the Patent Rights listed in Exhibit B to develop,
         manufacture, use, sell, exploit and otherwise commercialize any
         Patented Products, to practice any method, process or procedure, and to
         otherwise exploit the Patent Rights listed in Exhibit B, within the
         Field for the life of the Patent Rights, to the extent required to
         practice the Patent Rights listed in Exhibit A.

                  (b) The license granted under (a) above shall be exclusive and
         shall include the right to grant and authorize sublicenses within the
         Field under the Patent Rights; provided, however, that such sublicenses
         shall in each case include all applicable restrictions and limitations
         of this Agreement. Focal agrees to notify ETI in writing, within sixty
         (60) days, if and when any sublicenses are granted by Focal under the
         Patent Rights.

                  (c) Notwithstanding (a) above, Dr. Slepian and ETI reserve for
         themselves the perpetual right and license to use the Patent Rights for
         their own academic and/or internal research purposes and/or for any
         purpose outside the Field and/or for any purpose outside of the rights
         granted to Focal under this Agreement.

         2.2 ROYALTIES. In consideration of the rights and license granted to
Focal hereunder, Focal agrees to pay to ETI as a royalty the following amounts:

                  a)       For years 1 through 3:  $[**] per year;
                  b)       For years 4 through 6:  $[**] per year;
                  c)       For years 7 through 10:  The greater of $[**] per
                           year

                           or [**]% of the Net Revenue for sales of all
                           Patented Products under the Patent Rights (excluding
                           the sale of reusable equipment);

                  d)       For years 11 through the expiration of the last
                           patent within the Patent Rights:

                           [**]% of the Net Revenue for sales of all Patented
                           Products under the Patent Rights (excluding the
                           sale of reusable equipment)

In each year of the Agreement, the maximum amount of the royalty payment will be
limited to $[**] per year without provision for carryover to any other year.

<PAGE>

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

Reusable equipment is excluded from the royalty calculation because it is
anticipated that such equipment will be sold by Focal or its Affiliates at or
near its cost to Focal or its Affiliates to increase sales of disposable
products.

         2.3      YEARLY PAYMENTS.

                  (a) RESEARCH FUNDING. In addition to the payments under
         Section 2.2 Focal shall pay Dr. Slepian laboratory support which shall
         include $[**] per year for years 1 through 6. Such fees shall be paid
         quarterly.

                  (b) CONSULTING FEES. In addition to the payments under Section
         2.2 and Section 2.3 (a), Focal shall pay $[**] per year for years 1
         through 7 for consulting services as follows: $[**] directly to Dr.
         Slepian in monthly installments of $[**] each on the first day of each
         calendar month and $[**] directly to the University of Arizona in
         monthly installments of $[**] each on the first day of each calendar
         month.

                  (c) OVERHEAD. It is also understood that Focal shall pay [**]
         percent ([**]%) of the laboratory overhead per year as deemed by the
         University of Arizona or third party policy where Dr. Slepian is
         employed, but such overhead not to exceed $[**] per year. If the
         University of Arizona or any other institute Dr. Slepian is employed
         at, at a future date, involves an increase in overhead Focal shall
         negotiate in good faith with that party to achieve a mutually agreeable
         overhead rate.

         2.4      PAYMENT OF ROYALTIES

                  (a) REPORTS; PAYMENTS. All accrued royalties pursuant to
         Section 2.2 above will be due and payable quarterly. Focal will render
         payment to ETI within ninety (90) days after the end of each calendar
         quarter for all royalties that are due and payable and which accrued
         during such calendar quarter. Focal will provide with each royalty
         payment a written statement in reasonable detail setting forth Patented
         Products sold and the computation of the total Net Revenues from
         royalty-bearing worldwide sales during the period covered by such
         statement. If any payment is late, Focal will pay interest at the rate
         of one percent (1%) per month or the maximum rate permitted by law,
         whichever is lower, on any overdue amount from the date such overdue
         amount was due until such overdue amount is paid in full.

                  (b) CURRENCY. If any currency conversion is required in
         connection with the calculation of royalties hereunder, such conversion
         shall be made by using the exchange rates used by Focal in calculating
         its own revenues for financial reporting purposes.

                  (c) Any payments made by Focal or its Affiliates to ETI
         pursuant to this Agreement shall be in the full amount set forth,
         except that Focal may deduct any taxes, assessments, or charges levied
         against said payments by a foreign government or those required by
         statute to be withheld, up to a limit of ten percent (10%) but only to
         the extent that such taxes, assessments, or charges are ultimately
         available as a credit in the United States against the income tax
         payable by ETI. Focal shall furnish ETI with official receipt of any
         such taxes, assessments or charges withheld indicating ETI as a
         taxpayer.

<PAGE>

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

         2.5 BOOKS AND RECORDS. Focal will maintain a separate record in detail
reasonably sufficient to enable the Net Revenues and royalties to be determined.
Focal will permit such records to be examined at ETI's expense, upon at least
ten (10) days' written notice and no more than one time per calendar year, by an
auditor or accountant selected by ETI and to whom Focal has no reasonable
objection. Such examination may be conducted during business hours and shall be
limited to the extent reasonably necessary to verify the Net Revenues and
royalties. ETI and Dr. Slepian agree that all information obtained in the course
of such examination shall be deemed Confidential Information of Focal. In the
event the examination of the records reveals a short fall of [**] percent
([**]%) or more of the total payments due ETI in the period examined, Focal will
bear the entire cost of the examination of the records, and will pay the overdue
amount plus interest at the rate of one percent (1%) per month, or the maximum
permitted by law, whichever is lower, from the date such overdue amount was due
under Section 2.5.

                                    ARTICLE 3
                 DISCLOSURE AND PROTECTIVE OF PROPRIETARY RIGHTS

         3.1 DISCLOSURE. ETI and Dr. Slepian will promptly disclose to Focal all
aspects of the Improvements as may be conceived or developed from time to time
throughout the term of this Agreement. In addition, ETI agrees to provide to
Focal complete copies of all patent applications within the Patent Rights, and
all written materials pertaining thereto, including without limitation files of
any patent counsel involved in such applications. Upon request by Focal, Dr.
Slepian and ETI agree to provide reasonable assistance to Focal and its
representatives in understanding any or all such items. Focal agrees to pay
reasonable out-of-pocket costs paid to, non-employee third parties by ETI and
Dr. Slepian to provide materials or assistance requested by Focal under this
Section 3.1, provided that ETI or Dr. Slepian obtained Focal's prior written
approval of such expenditures.

         3.2 FILING, PROSECUTION AND MAINTENANCE BY FOCAL. Focal will have the
obligation to take responsibility for, and control of, the filing for,
prosecution and maintenance of the Patent Rights and/or Improvements in ETI's or
Dr. Slepian's name, with the input and participation of ETI and Dr. Slepian. Dr.
Slepian and ETI shall cooperate with and assist Focal in connection with the
filing for, prosecution and maintenance of the Patent Rights and/or
Improvements, and in evidencing and perfecting the rights granted to Focal under
this Agreement, and Focal shall keep ETI fully informed as to the status of the
Patent Rights and/or Improvements. Dr. Slepian and ETI shall have full access to
the files relating to the Patent Rights and/or Improvements, whether at Focal's
office or at its counsel's office, for use by Dr. Slepian or ETI for purposes or
use outside the Field.

         3.3 FILING, PROSECUTION AND MAINTENANCE BY ETI. In the event Focal
elects not to pursue a patent application within the Patent Rights and/or
Improvements within sixty (60) days after receipt of all information and
materials therefor from Dr. Slepian and ETI pursuant to Section 3.1, or elects
not to maintain an issued patent, within the Patent Rights in any particular
country, ETI may pursue the same in such country at its own expense. In such
event Focal will, at ETI's request, cooperate with ETI in obtaining and/or
maintaining such patents, including but not limited to providing ETI with
applicable documents and information in Focal's possession, as reasonably
requested by ETI.

<PAGE>

Focal agrees to inform ETI of its decision to abandon a patent or application in
any country at least sixty (60) days prior to the date such abandonment would be
effective, to enable ETI to continue the prosecution or maintenance of such
application or patent.

         3.4      CONFIDENTIAL INFORMATION.

                  (a) GENERAL. The term "Confidential Information" as used in
         this Agreement will include all proprietary information concerning the
         Patent Rights and/or Improvements. With respect to the obligations of
         ETI and Dr. Slepian under this Section 3.4, "Confidential Information"
         shall also include any information provided by Focal to Dr. Slepian or
         ETI in a tangible form marked "confidential" or with a similar
         designation or that Focal disclosed to ETI or Dr. Slepian orally and
         confirmed such information in writing as confidential within thirty
         (30) days after its initial disclosure. Each party agrees to maintain
         the confidentiality of the Confidential Information, not to disclose
         such Confidential Information to third parties, and to take all
         reasonable efforts to make the Confidential Information known only to
         those employees or authorized representatives who need to have access
         to the Confidential Information. Notwithstanding the foregoing, Focal
         may disclose information concerning the Patent Rights and/or
         Improvements to actual or prospective sublicensees, and to such other
         persons and in such other manner as Focal deems reasonably necessary in
         connection with its business, provided such disclosees shall sign an
         agreement corresponding to the same terms of confidentiality herein to
         protect the confidentiality of Dr. Slepian and ETI and such agreement
         provides for Dr. Slepian and/or ETI to enforce such confidentiality
         agreement.

                  (b) EXCEPTIONS. However, neither ETI nor Dr. Slepian, on the
         one hand, nor Focal, on the other hand, will have any obligation of
         confidence under this Agreement with respect to any information which:

                           (i) was at the time of disclosure thereof, already
                  known to such party other than from the disclosing party; or

                           (ii) without breach of this Agreement, has been
                  published or is otherwise available to the public at any time
                  whether before or after the time of disclosure to such party;

                           (iii) is at any time lawfully received by such party
                  from a third party who has no obligation of confidence to a
                  party hereto in respect thereof;

                           (iv) was independently developed by or for the
                  receiving party without reference to or reliance upon the
                  Confidential Information, or

                           (v) was required to be disclosed by the receiving
                  party to comply with applicable laws, to defend or prosecute
                  litigation or to comply with governmental regulations,
                  provided that, the receiving party provides prior written
                  notice of such disclosure to the disclosing party and takes
                  reasonable and lawful action to avoid and/or minimize the
                  degree of such disclosure.

<PAGE>

         Any information which is within (i), (ii), (iii), (iv) or (v) above
         shall not be included within the definition of Confidential Information
         for purposes of this Section 3.4. Notwithstanding the foregoing, it is
         understood that Dr. Slepian and ETI shall not be relieved of their
         obligations under this Section 3.4 not to disclose to third parties
         information concerning the Patent Rights and/or Improvements by reason
         of (i), (iii), (iv) or (iv) above.

3.5      PUBLICATIONS

                  (a) Notwithstanding any provision of this Agreement to the
         contrary, Dr. Slepian shall have the right to publish academic papers
         and make scientific presentations regarding his research. Such papers
         or presentations may disclose Improvements only to the extent that
         Focal has chosen not to enter into an agreement for exclusive rights in
         such Improvements pursuant to Section 3.7. However, the parties agree
         that prior to public disclosure of any such paper or presentation by
         Dr. Slepian, Dr. Slepian shall provide to Focal a copy of such paper or
         presentation at the time such paper or presentation is submitted for
         publication or presentation, but in any case at least ninety (90) days
         prior to the date of the proposed public disclosure, in order for Focal
         to have sufficient time to file any patent applications that Focal
         deems appropriate.

                  (b) In the event that Focal or its personnel propose to make a
         public disclosure or publication that pertains to work performed in
         whole or in part by Dr. Slepian and to which Focal has exclusive rights
         under this Agreement, Focal agrees to give appropriate credit to Dr.
         Slepian for his contributions.

         3.6 IMPROVEMENTS. Dr. Slepian shall own the entire right, title and
interest in and to all Improvements acquired, made or developed solely or
jointly with Focal and/or any third party.

         3.7 RIGHT FOR IMPROVEMENTS. Dr. Slepian shall give Focal written notice
describing any developed Improvements in general terms. Dr. Slepian and Focal
agree to negotiate in good faith exclusively for rights in any such Improvements
for a period of ninety (90) days following Focal's receipt of such written
notice before Dr. Slepian offers the rights to any such Improvements to any
third party. In the event Dr. Slepian and Focal have not agreed upon the terms
and conditions for any such rights in the Improvements within such ninety (90)
day period after initiating negotiations Dr. Slepian shall be free to negotiate
and enter into an agreement with a third party relating to rights in such
Improvements without further obligations to Focal, provided that Dr. Slepian
shall not enter into an agreement with any such third party under terms and
conditions substantially more favorable to the third party than the terms and
conditions last presented to Focal unless such more favorable terms and
conditions are presented to Focal and, within thirty (30) days after receipt by
Focal, Focal does not accept such more favorable terms and conditions in writing
(executed agreement).

<PAGE>

                                    ARTICLE 4
                            WARRANTIES: INFRINGEMENT

         4.1 WARRANTIES. ETI and Dr. Slepian, each represents and warrants to
Focal the following:

                  (a) Dr. Slepian and ETI together have the full right and
         authority to enter into this Agreement and grant the rights and
         licenses granted herein;

                  (b) As of the Effective Date, ETI owns all right, title and
         interest in and to the Patent Rights;

                  (c) Dr. Slepian and ETI have not previously granted, and shall
         not grant except as provided in this Agreement, during the term of this
         Agreement, any rights in the Patent Rights to a party other than Focal;

                  (d) As of the Effective Date, to the knowledge of Dr. Slepian
         and ETI, but without conducting an independent investigation beyond the
         pending applications for Patent Rights: (i) no claim within the
         existing Patent Rights is dominated by a claim of any patent or patent
         application of a third party in any country; does not and will not
         infringe any patent rights, or other proprietary rights of any third
         party;

                  (e) As of the Effective Date, to the knowledge of Dr. Slepian
         and ETI, except for certain claims made by Cleveland Clinic described
         in that certain letter dated July 31, 1992 from Dr. Slepian to Focal
         and incorporated herein by reference, (I) there have been no actions,
         suits or claims made or threatened (including, without limitation,
         claims by former employers or collaborators) against Dr. Slepian, ETI
         or, to their knowledge, any third party, with respect to the Patent
         Rights or the right of Dr. Slepian or ETI to enter into and perform
         their obligations under this Agreement and (ii) there has been no legal
         action, suit or investigation made, brought or threatened by or against
         ETI or Dr. Slepian with respect to any matter that is material to the
         performance by Dr. Slepian and ETI of their obligations under this
         Agreement in any respect; and

                  (f) As of the Effective Date, to the knowledge of Dr. Slepian
         and ETI, based upon the inventions claimed in the Patent Rights, all
         scientific data provided by ETI or Dr. Slepian to Focal in tangible
         form are accurate, and ETI or Dr. Slepian has disclosed to Focal all
         information known to them that would be material in evaluating the
         safety or efficacy of any Patented Product.

         4.2 LIMITATION. EXCEPT FOR THE WARRANTIES IN SECTION 4.1, NEITHER ETI
NOR DR. SLEPIAN MAKES ANY OTHER WARRANTY WITH RESPECT TO THE PATENT RIGHTS, THE
OPERATION, PERFORMANCE OR RESULTS OF USING THE PATENT RIGHTS, THE USES TO WHICH
THE PATENT RIGHTS MAY BE PUT OR THAT THE PATENTED PRODUCTS WILL NOT INFRINGE
PATENT RIGHTS OR OTHER RIGHTS OF THIRD PARTIES. THE WARRANTIES MADE BY DR.
SLEPIAN AND ETI IN SECTION 4.1 ARE MADE IN LIEU OF ALL OTHER EXPRESS OR IMPLIED
WARRANTIES INCLUDING

<PAGE>

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY
PARTICULAR PURPOSE UNDER NO CIRCUMSTANCES, DURING OR AFTER THE TERM OF THIS
AGREEMENT, WILL ETI OR DR. SLEPIAN BE RESPONSIBLE FOR CONSEQUENTIAL OR
INCIDENTAL DAMAGES INCURRED BY OR IMPOSED ON FOCAL BY REASON OF THE USE OF THE
PATENT RIGHTS OR ARISING OUT OF THE USE, OPERATION OR PERFORMANCE OF ANY OF THE
PATENTED PRODUCTS MANUFACTURED, USED OR SOLD BY FOCAL, EXCEPT AS PROVIDED BELOW
IN SECTION 4.3.

         4.3 EFFECT OF REPRESENTATIONS AND WARRANTIES. It is understood that if
the representations and warranties made by Dr. Slepian and ETI under Section 4.1
are not true and accurate, and Focal incurs damages, liabilities, costs or other
expenses as a result of such falsity, ETI and Dr. Slepian shall indemnify and
hold Focal harmless from and against any such damages, liabilities, costs or
expenses incurred as a result of such falsity, provided that ETI and/or Dr.
Slepian receives prompt notice of any claim resulting from or related to such
falsity. However, the parties agree that ETI's and Dr. Slepian's liability under
this Section 4.3 shall not exceed the amounts paid and payable to them,
collectively, by Focal under this Agreement, and that such payments (together
with the right to terminate this Agreement under section 6.2 below) shall be the
sole remedy available to Focal in event of a breach of the representations and
warranties made under Section 4.1 above.

         4.4 INFRINGEMENT BY THIRD PARTIES. If either party determines that a
third party is making, using or selling a product that may infringe the Patent
Rights, that party will promptly notify the other party in writing within ninety
(90) days of such determination. Focal shall have the exclusive right (itself or
through others), at its sole option, to bring suit against such alleged
infringer. All recoveries in such suit (whether initiated by Focal or its
sublicensee, or brought as a counterclaim in a suit commenced by a third party)
will inure to the benefit of Focal or its designee, less, a one time royalty
payment to ETI; such royalty will equal three-tenths percent (0.3%) of the
amount recovered. ETI and Dr. Slepian will cooperate with, and assist Focal and
its designees in, the pursuit of any suit, including without limitation by
joining as a nominal party and executing such documents; as may be reasonably
required. Focal will reimburse ETI and Dr. Slepian for reasonable out-of-pocket
expenses paid to non-employee third parties directly as a result of assistance
so requested by Focal, provided however, that such expenses were previously
approved by Focal. Furthermore, Focal shall reasonably compensate Dr. Slepian
for his time spent providing any assistance so requested by Focal.

         4.5 INFRINGEMENT BY PATENTED PRODUCT(S). If Focal or a sublicensee,
distributor or dealer is sued by a third party charging infringement of patent
rights that dominate a claim of the Patent Rights with respect to the
manufacture, use, distribution or sale of a Patented Product, Focal will
promptly notify ETI. As between the parties to this Agreement, Focal will be
entitled to control the defense in any such action(s) and withhold [**] of the
royalties related to such Patented Product (as the case may be) otherwise
payable to ETI and use the withheld royalties to reimburse the legal defense
costs, attorneys' fees and liability incurred in such infringement suit(s).
Notwithstanding, Focal agrees to withhold only that portion of such royalties as
may reasonably be necessary to reimburse amounts in accordance with this Section
4.5. If Focal is required to pay a royalty to a third party to make, use,
distribute and/or sell a Patented Product as a result of a final judgment or
settlement, the royalties payable to ETI in relation to such Patented Product
will be reduced by one-half. In the event Focal is successful in defending
against any such claims or actions, once Focal

<PAGE>

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

is compensated for [**] percent ([**]%) of its legal defense costs in defending
such claims or actions, Focal will return any remaining withheld royalties to
ETI.

                                    ARTICLE 5
                               AGREEMENTS OF FOCAL

         5.1 INDEMNIFICATION Except for claims covered by Section 4.3 above,
Focal will, at Focal's cost and expense, defend, indemnify and hold harmless Dr.
Slepian and his personal representatives and assigns and ETI, its shareholders,
officers, directors, employees, agents, representatives, successors and assigns
from and against any and all liabilities, damages, and expenses, including but
not limited to attorneys' fees, paid by such parties to third parties during or
after the term of this Agreement, by reason of any charge, claim or legal action
by any third person, including but not limited to an employee, agent or
representative of Focal, relating to or arising out of injuries, deaths,
illnesses or related damages sustained or injured by such person or entity that
results from or in any way, directly or indirectly, is connected with the
manufacture, sale or use of any Patented Product by Focal; provided, however,
that Focal will defend and have sole control over the defense of any action
against such parties, and ETI and Dr. Slepian will promptly notify Focal of any
action related to the Patented Products, of which they become aware.
Notwithstanding the foregoing, Focal shall have no liability under this Section
5.1 to the extent that any injury, death, illness or damages are reasonably
attributable (a) to the failure of ETI or Dr. Slepian to disclose to Focal
material information known to ETI or Dr. Slepian (and not known to Focal)
regarding the safety Patented Products or (b) the negligence or willful
misconduct of ETI or Dr. Slepian.

         5.2 PATENT MARKING. Focal will mark all Patented Products sold by it
with the number of any applicable patent within the Patent Rights; in such form
as satisfies the marking provisions of the United States or any other applicable
patent laws and regulations. Until such time as an applied for patent is issued,
all Patented Products will be marked to disclose that a patent application is
pending. Focal will comply with, and this Agreement will be subject to, all
laws, rules and regulations of the United States that may be applicable to the
disclosure of the Patent Rights and the sale or export of the Patented Products.

         5.3 INSURANCE. During the term of this Agreement and for (a) ten (10)
years after the end of the term of this Agreement or (b) the expiration of the
last to expire patent within the Patent Rights, whichever is longer, Focal will
obtain and maintain at its expense product liability insurance, in which ETI and
Dr. Slepian shall be named as additional insured against all claims, demands or
causes of action arising out of alleged defects in or out of the use of Patented
Products made by Focal. The limits of liability of such insurance applicable to
ETI and Dr. Slepian will not be less than the limits of liability from time to
time generally applicable to Focal for comparable products manufactured and sold
by Focal, but in no event will such limits be less than a combined single limit
of $[**] prior to the first commercial sale in the United States of a Patented
Product or less than a combined single limit of $[**] thereafter.
Notwithstanding the foregoing, Focal shall not be obligated to maintain product
liability insurance under this Section 5.3 until the commencement of human
clinical trials for a Patented Product, or to the extent that Focal self-insures
such liability and has the financial resources reasonably necessary to do so.

<PAGE>

         Each insurance policy will provide that it may not be cancelled or
amended without giving at least thirty (30) days' prior notice to ETI and Dr.
Slepian. Upon request by ETI or Dr. Slepian, Focal will provide ETI with a
certificate or certificates of its insurance company or companies evidencing
that such insurance has been obtained and setting forth the limits of liability.
Upon request by ETI or Dr. Slepian, not less than thirty (30) days prior to the
expiration of any such insurance, Focal will provide ETI with an insurance
certificate or certificates of its insurance company or companies evidencing
that such insurance has been extended or that the new insurance coverage has
been obtained by Focal and setting forth the limits of liability. With each such
certificate by an insurance company or companies, an officer of Focal will
certify that the limits of liability applicable to ETI and Dr. Slepian are not
less than the limits of liability generally applicable to Focal for comparable
products manufactured and sold by it. The insurance coverage obtained by Focal
for ETI and Dr. Slepian, pursuant to the provisions of this Section, will be
provided by the same insurance companies that provide comprehensive general
liability insurance, including product liability insurance, to Focal for the
Patented Products. If the companies providing insurance for Focal are changed,
the companies providing insurance for ETI and Dr. Slepian will be changed so
that the same companies are providing insurance for both Focal and ETI and Dr.
Slepian.

                                    ARTICLE 6
                              TERM AND TERMINATION

         6.1 TERM. This Agreement shall become effective as of the Effective
Date and, unless earlier terminated pursuant to the other provisions of this
Article 6, shall continue in full force and effect until the later of (a) the
expiration of the last-to-expire patent within the Patent Rights; (b) the
abandonment of the last patent application within the Patent Rights; or (c) the
date royalties cease to accrue under Section 2.2 above. Upon the expiration of
this Agreement, Focal's license under Section 2.1 with respect to Patented
Products shall survive, provided that such license shall thereafter be
non-exclusive and royalty free.

         6.2 DEFAULT. If either party materially breaches this Agreement
(including a material breach of any warranty under Section 4.1 above, which
breach has a materially adverse effect on the other party), the other party may
elect to give such party written notice describing the alleged default. If the
party in default has not cured such default within thirty (30) days after
receipt of such notice or, assuming the default can be cured, commenced to cure
such default within such thirty (30) days after receipt of notice and cured such
default within ninety (90) days after receipt of notice, the notifying party
will be entitled, in addition to any other rights it may have under this
Agreement, to terminate this Agreement by giving notice to take effect
immediately. If either party receives notification from the other of a default
and if the party alleged to be in default notifies the other party in writing
within thirty (30) days of receipt of such default notice that it disputes the
asserted default, the matter will be submitted to arbitration as provided in
Section 7.2 of this Agreement. In such event, the non-breaching party shall not
have the right to terminate this Agreement until it has been determined in such
arbitration proceeding that the other party materially breached this Agreement,
and the breaching party fails to cure such breach within ninety (90) days after
the conclusion of such arbitration proceeding.

<PAGE>

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

         6.3 TERMINATION BY FOCAL Focal may terminate this Agreement by ninety
(90) days prior written notice to ETI and Dr. Slepian if Focal is no longer
researching and developing, manufacturing, using, selling, exploiting and/or
otherwise commercializing the Patent Rights and/or Improvement. In the event of
termination by Focal, Focal shall be responsible for payment of all patent
maintenance fees as per a declining schedule which will be [**]% year 1, [**]%
year 2, and [**]% year 3 from the date of termination. Furthermore, Focal shall
also pay Dr. Slepian and ETI upon termination [**] ($[**]) Dollars as an early
termination penalty. Upon a termination of this Agreement in its entirety under
this Section 6.3, all rights and obligations of the parties shall terminate,
except as provided in 6.5 below and the termination shall not relieve Focal of
any obligations accrued prior to such termination. Upon termination Focal shall
return to ETI all written materials provided by ETI or Dr. Slepian to Focal
containing Confidential Information of ETI or Dr. Slepian; provided, however,
that Focal may retain one (1) copy of such Confidential Information for archival
purposes. Upon such a termination of this Agreement, Focal shall consider
granting to ETI a license to improvements made by Focal with respect to the
products for which Focal has terminated all of its activities, on such terms as
may be mutually agreed.

         6.4 BANKRUPTCY. To the extent permitted by applicable law, in the event
that:

                  (a) Focal (i) applies for or consents to the appointment of,
         or the taking of possession by, a receiver, custodian, trustee or
         liquidator of all or substantially all of its property, (ii) makes a
         general assignment for the benefit of its creditors, (iii) commences a
         case under the United States Bankruptcy Code, or files a petition
         seeking to take advantage of any other law relating to bankruptcy,
         insolvency, or composition or readjustment, with respect to
         substantially all of its debts, or (iv) adopts any resolution of its
         board of directors or stockholders for the purpose of effecting any of
         the foregoing; or

                  (b) a proceeding or case is commenced without the application
         or consent of Focal that seeks a remedy described in (a) above and such
         proceeding or case continues undismissed, or an order, judgment or
         decree approving or ordering any of such remedies shall be entered and
         continue unstayed and in effect, for a period of sixty (60) days from
         and after the date service of process is effected upon Focal;

then in any such event, all rights under this Agreement will be deemed to have
terminated, except as provided in Section 6.5, as of a date seven (7) days prior
to that event, except those obligations concerning confidentiality, which shall
survive termination of this Agreement for any reason.

         6.5 SURVIVAL. The provisions of Articles 1, 4, 5 and 7, and of Sections
3.4, 3.5, 3.6, 6.3 and 6.5 shall survive and continue in effect after the
expiration or any termination of this Agreement, except that:

                  (a) Upon a termination under Section 6.2 above by reason of a
         breach by Focal, or a termination of this Agreement in its entirety
         under Section 6.3 above, the provisions of Article 4 shall terminate
         and not so survive;

                  (b) Upon any termination of this Agreement, other than under
         Section 6.3 above, any sublicense granted hereunder shall survive,
         provided that the sub-licensee promptly agrees in writing to be bound
         by the applicable provisions of this Agreement. It is

<PAGE>

         understood that survival of such sublicense shall not imply any
         continued license to Focal hereunder; and in no event shall ETI or Dr.
         Slepian be required to assume any obligations of Focal that extend
         beyond or that are in any way more burdensome than the obligations of
         ETI or Dr. Slepian to Focal hereunder; and

                  (c) ETI's right to receive royalties that accrued prior to any
         expiration or termination of this Agreement shall also survive.

                                    ARTICLE 7
                                     GENERAL

         7.1 NOTICES. Any notice required or permitted to be given under this
Agreement will be sufficient if in writing and delivered personally or by
registered or certified mail, postage prepaid and return receipt requested, as
follows (or to such other address as the parties will designated by notice to
the other in accordance with this Section 7.1) and will be deemed to have been
given as of the date of personal delivery, or as of the date on the receipt or
as of the date returned unclaimed if sent by registered or certified mail:

                  If to Focal:              Focal, Inc.
                                            4 Maguire Road
                                            Lexington, MA  02421
                                            Attention:  Robert J. Depasqua
                  If to Dr. Slepian
                  or ETI:                   Marvin J. Slepian, M.D.
                                            Endoluminal Therapeutics, Inc.
                                            5001 N. Summit Ridge Road
                                            Tucson, Arizona 85750

         7.2 ARBITRATION. Any dispute, controversy or claim of either party
arising out of, in relation to, or in connection with this Agreement will be
finally settled by binding arbitration under the Licensing Agreement Arbitration
Rules of the American Arbitration Association by a panel of three (3)
arbitrators appointed in accordance with such rules. ETI and Focal shall each
choose one (1) arbitrator and the first two (2) arbitrators shall both choose
the third arbitrator. The arbitrators shall apply the laws of the Commonwealth
of Massachusetts to the merits of any dispute, controversy or claim, without
regard to conflicts of law principles. Judgment upon the award rendered by the
arbitrators may be entered in any court having jurisdiction thereof. The place
of arbitration will be Tucson, Arizona if Focal brings such dispute, controversy
or claim to arbitration and shall be Boston, Massachusetts if ETI or Dr. Slepian
brings such dispute, controversy or claim to arbitration. The parties agree that
the arbitrators may grant injunctive relief. Notwithstanding the foregoing,
before appointment of the arbitrators and in exceptional circumstances even
thereafter, either party to this Agreement may apply to any court of competent
jurisdiction for a temporary restraining order, preliminary injunction, or other
interim or conservatory relief, as necessary, without breach of this Section 7.2
and without any abridgment of the power of the arbitrators. The parties agree
that, any provision of applicable law notwithstanding, they will not request,
and the arbitrators shall have no authority to award, punitive or exemplary
damages against any party except

<PAGE>

as provided in Article 4 herein. The costs of any arbitration, including without
limitation administrative and arbitrator's fees, shall be shared equally by the
parties. Each party shall bear the cost of its own attorneys' fees and expert
witness fees, if any.

         7.3 RELATIONSHIP OF THE PARTIES. The relationship of the parties is
that of independent contractors, and nothing contained herein will constitute
the parties to be partners, joint venturers, or agents of the other, or to
create the relationship of employer and employee.

         7.4 FORCE MAJEURE. Neither party will be responsible to the other party
for non-performance or delay in performance of any terms or conditions of this
Agreement due to acts of God, acts of governments, wars, riots, strikes,,
accidents in transportation, or other causes beyond its reasonable control even
though not similar in nature to those enumerated.

         7.5 GOVERNING LAW. This Agreement will be governed by and construed and
enforced in accordance with the laws of the State of Arizona, without regard to
conflict of law principals.

         7.6 ASSIGNMENT. This Agreement shall not be assignable by a party
hereto without the prior written consent of Focal and Dr. Slepian and ETI, which
consent shall not be withheld unreasonably. Notwithstanding the foregoing, upon
written notice to Dr. Slepian and ETI, Focal may transfer and assign this
Agreement, to an entity that succeeds to substantially all of its business or
assets relating to this Agreement and such party must assume in writing, all
obligations and liabilities of Focal under this Agreement. Upon prior written
notice to Focal, without its consent, ETI may assign to any third party its
right to receive royalty payments hereunder. This Agreement shall inure to and
be binding upon successors and assigns of a party hereto.

         7.7 WAIVER. No waiver of any breach of any provision of this Agreement
will constitute a waiver of any prior, concurrent, or subsequent breach of the
same or any other provisions hereof, and no waiver will be effective unless made
in writing.

         7.8 MODIFICATIONS. This Agreement can be modified or amended only by
written agreement duly signed by the parties.

         7.9 SEVERABILITY. If any provision of this Agreement is held to be
illegal, invalid or unenforceable under present or future laws effective during
the term hereof, such provision will be fully severable; this Agreement will be
construed and enforced as if such illegal, invalid or unenforceable provision
had never comprised a part hereof; and the remaining provisions of this
Agreement will remain in full force and effect.

         7.10 COMPLETE AGREEMENT This Agreement sets forth the entire agreement
and understanding of the parties in respect of the transactions contemplated
hereby and supersedes al1 prior agreements, arrangements and understandings
relating to the subject matter hereof, except the agreement between the parties,
dated on or about the date hereof, relating to the termination of an exclusive
license agreement, dated as of August 7, 1992, between the parties, attached
hereto as Exhibit D.

         7.11 NO IMPLIED OBLIGATIONS It is understood that nothing in this
Agreement shall be deemed to prevent Focal from commercializing products similar
to or competitive with Patented

<PAGE>

Products provided that the foregoing does not relieve Focal of any of its
obligations under this Agreement.

         7.12 NO CONSEQUENTIAL DAMAGES. EXCEPT AS PROVIDED IN ARTICLE 4, IN NO
EVENT SHALL EITHER PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL
DAMAGES ARISING OUT OF ANY BREACH OF THIS AGREEMENT.

         7.13 COUNTERPARTS AND HEADINGS. This Agreement may be executed in
counterparts, each of which shall be deemed to be an original and both together
shall be deemed to be one and the same agreement. All headings, the cover page
and the table of contents in this Agreement are inserted for convenience of
reference only and shall not affect its meaning or interpretation.

         7.14 CONFIDENTIAL TERMS. Each party agrees not to disclose any terms of
this Agreement to any third party without Focal's, ETI's and Dr Slepian's
written consent, except as required by securities or other applicable laws, to
prospective investors and/or to such party's accountants, attorneys and other
professional advisors.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement
effective as of the day and year first above written.

MARVIN J. SLEPIAN, M.D.                    FOCAL

   ("Dr. Slepian")                             ("Focal")

By:/s/ Marvin J. Slepian                       By: /s/ Robert J. Depasqua
   ---------------------------                    ----------------------------
    Marvin J. Slepian, M.D.                        Robert J. Depasqua
                                                   President and
                                                   Chief Executive Officer

ENDOLUMINAL THERAPEUTICS, INC.
   ("ETI")

By: /s/ Marvin J. Slepian
   ---------------------------
   Marvin J. Slepian, M.D.
   President

<PAGE>

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

                                                     EXHIBIT A

<TABLE>
<CAPTION>

      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      Family        ID             Status      Title                               Inventors       Serial/Patent File/Issue
                                                                                                   Number        Date
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      <S>           <C>            <C>         <C>                                 <C>             <C>           <C>
      [**]          [**]           [**]        [**]                                [**]            [**]      8/25/95
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]                          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------
      [**]          [**]           [**]        [**]                                [**]            [**]          [**]
      ------------- -------------- ----------- ----------------------------------- --------------- ------------- ---------

</TABLE>

<PAGE>

      -------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
      -------------------------------------------------------------------

<TABLE>
<CAPTION>

                                                     EXHIBIT B
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------
Family       ID          Status    Title                                         Inventors    Serial/Patent      File/Issue
                                                                                              Number             Date
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------
<S>          <C>         <C>       <C>                                           <C>          <C>                <C>
[**]         [**]        [**]      [**]                                          [**]         [**]               [**]
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------
[**]         [**]        [**]      [**]                                          [**]         [**]               [**]
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------
[**]         [**]        [**]      [**]                                          [**]         [**]               [**]
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------
[**]         [**]        [**]      [**]                                          [**]         [**]               [**]
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------
[**]         [**]        [**]      [**]                                          [**]         [**]               [**]
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------
[**]         [**]        [**]      [**]                                          [**]         [**]               [**]
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------
[**]         [**]        [**]      [**]                                          [**]         [**]               [**]
------------ ----------- --------- --------------------------------------------- ------------ ------------------ ------------

</TABLE>

<PAGE>

                                    EXHIBIT C

                             [CONSULTING AGREEMENT]

               [FILED WITH THE COMMISSION AS A SEPARATE EXHIBIT]

<PAGE>

                                    EXHIBIT D

          TERMINATION OF EXCLUSIVE LICENSE AGREEMENT OF AUGUST 7, 1992

<PAGE>

                   TERMINATION OF EXCLUSIVE LICENSE AGREEMENT

         This Termination of Exclusive License Agreement (the "Termination
Agreement") is made and entered into effective as of the ___ day of
____________, 2000, by and among Marvin J. Slepian, M.D. ("Dr. Slepian"),
Endoluminal Therapeutics, Inc., a Delaware corporation ("ETI") and Focal, Inc.,
a Delaware corporation ("Focal").

                                    RECITALS

         A. Dr. Slepian, ETI and Pegas Pharmaceuticals, Inc., a Delaware
corporation to which Focal is the successor-in-interest, entered into an
Exclusive License Agreement effective as of August 7, 1992 (the "License
Agreement").

         B. Dr. Slepian, ETI and Focal desire to terminate the License Agreement
and set forth the terms and conditions relating to said termination.

         NOW, THEREFORE, for and in consideration of the mutual covenants and
agreements contained herein, the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

         1. Notwithstanding Section 7.1, or any other provision, of the License
Agreement, Focal retains no license whatsoever under the License Agreement.

         2. The provisions enumerated in Section 7.5 of the License Agreement
shall survive with respect to the parties' rights and obligations accrued
thereunder, as provided in the License Agreement, except that Article 1 and
Sections 4.2(b) and 7.5(a), (b) and (c) shall not survive.

         3. Focal represents and warrants that there have been sublicenses
granted under the License Agreement. Such sublicenses shall remain in full force
and effect and shall continue under a new Exclusive License Agreement by and
among Dr. Slepian, ETI and Focal, of even date herewith, in accordance with its
terms.

         4. Except as provided in this Termination Agreement, the License
Agreement is terminated, null and void and of no further effect.

         5. This Termination Agreement may be executed in counterparts, each of
which shall be deemed an original and both together shall be deemed to be one
and the same agreement.

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Termination
Agreement effective as of the day and year first above written.

                                         FOCAL, INC.
                                              ("Focal")

                                         By: /S/ Robert J. DePasqua
                                         Robert J. DePasqua
                                         President and Chief Executive Officer

                                         MARVIN J. SLEPIAN, M.D.
                                              ("Dr. Slepian")

                                         By: /s/ Marvin J. Slepian
                                         Marvin J. Slepian, M.D.

                                         ENDOLUMINAL THERAPEUTICS, INC.
                                              ("ETI")

                                         By: /s/ Marvin J. Slepian
                                         Marvin J. Slepian, M.D.
                                         President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]